← Kymera Therapeutics overview

Kymera Therapeutics vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Kymera Therapeutics Inc (KYMR)

Q3 2026
▲3▼1

Kymera's lead drug KT-621 hits key enrollment milestone early, pulling data forward

  • KT-621 trial enrollment completed early Kymera finished enrolling patients in a mid-stage trial of KT-621 for atopic dermatitis about six months ahead of schedule. That pulls the key data readout forward to the end of 2026, speeding up the path to a possible approval and making the drug more valuable.

    This is the core event that drove the stock and is new this period.

  • Analyst upgrades and price target hikes After the enrollment news, several analysts raised their price targets, with Canaccord lifting its target to $129 from $106. Upgrades can bring in new buyers and support a higher stock price.

    Analyst reactions are a direct market driver and new this period.

  • Strong pipeline and partnership milestones Kymera reported $65 million in second-quarter collaboration revenue, including a $20 million Sanofi milestone and a $45 million Gilead payment. With about $1.5 billion in cash, the company is funded into 2029, reducing the need to raise money and boosting confidence.

    Financial strength and partnership validation are new and support the stock.

  • Insider share sale A board member's venture fund sold nearly 400,000 shares for about $44 million under a pre-arranged plan. While such sales are common, they can signal that a well-informed investor sees limited upside and may weigh on the stock.

    This is a real counterweight to the positive news and is new this period.

July 2026
▲3▼1

Kymera's lead drug KT-621 hits key enrollment milestone early, pulling data forward

  • KT-621 trial enrollment completed early Kymera finished enrolling patients in a mid-stage trial of KT-621 for atopic dermatitis about six months ahead of schedule. That pulls the key data readout forward to the end of 2026, speeding up the path to a possible approval and making the drug more valuable.

    This is the core event that drove the stock and is new this period.

  • Analyst upgrades and price target hikes After the enrollment news, several analysts raised their price targets, with Canaccord lifting its target to $129 from $106. Upgrades can bring in new buyers and support a higher stock price.

    Analyst reactions are a direct market driver and new this period.

  • Strong pipeline and partnership milestones Kymera reported $65 million in second-quarter collaboration revenue, including a $20 million Sanofi milestone and a $45 million Gilead payment. With about $1.5 billion in cash, the company is funded into 2029, reducing the need to raise money and boosting confidence.

    Financial strength and partnership validation are new and support the stock.

  • Insider share sale A board member's venture fund sold nearly 400,000 shares for about $44 million under a pre-arranged plan. While such sales are common, they can signal that a well-informed investor sees limited upside and may weigh on the stock.

    This is a real counterweight to the positive news and is new this period.

Latest
▲3▼1

Kymera's lead drug KT-621 hits key enrollment milestone early, pulling data forward

  • KT-621 trial enrollment completed early Kymera finished enrolling patients in a mid-stage trial of KT-621 for atopic dermatitis about six months ahead of schedule. That pulls the key data readout forward to the end of 2026, speeding up the path to a possible approval and making the drug more valuable.

    This is the core event that drove the stock and is new this period.

  • Analyst upgrades and price target hikes After the enrollment news, several analysts raised their price targets, with Canaccord lifting its target to $129 from $106. Upgrades can bring in new buyers and support a higher stock price.

    Analyst reactions are a direct market driver and new this period.

  • Strong pipeline and partnership milestones Kymera reported $65 million in second-quarter collaboration revenue, including a $20 million Sanofi milestone and a $45 million Gilead payment. With about $1.5 billion in cash, the company is funded into 2029, reducing the need to raise money and boosting confidence.

    Financial strength and partnership validation are new and support the stock.

  • Insider share sale A board member's venture fund sold nearly 400,000 shares for about $44 million under a pre-arranged plan. While such sales are common, they can signal that a well-informed investor sees limited upside and may weigh on the stock.

    This is a real counterweight to the positive news and is new this period.

Abcellera Biologics Inc (ABCL)

Q3 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

© 2026 MarketDXWhy